Company news
Coiled Therapeutics Plc (LSE:COIL) news
Coiled Therapeutics Plc news releases on 6ix. Latest, Oct 1, 2026: Investor Presentation via Engage Investor
Press releases & updates
Investor Presentation via Engage Investor
October 1, 2026
Participation in The Small Cap Showcase
September 30, 2026
Interim Results to 30 June 2026
September 28, 2026
Successful Enrolment Completed Across Two Cohorts
September 21, 2026
Appointment of Joint Corporate Broker
September 1, 2026
Change of Registered Office
August 10, 2026
First Patient Dosed with new Formulation of AO-252
August 3, 2026
Coiled Advances Next-Generation AO-252 Formulation
July 7, 2026
Appointment of Independent Non-Executive Director
June 24, 2026
Life Sciences Investor Forum
June 19, 2026
Proactive One2One Investor Forum
June 18, 2026
Grant of Share Options
June 17, 2026
Appointment of Ozgur Sahin as Scientific Advisor
June 8, 2026
Attendance at Endless Frontier Labs 2026
May 7, 2026
Presentation at 18th Annual World Cancer Congress
April 15, 2026
Clinical Trial Update
April 8, 2026
Total Voting Rights
April 1, 2026
Readmission - Roquefort Therapeutics Plc
March 27, 2026
Investor Presentation
March 26, 2026
Lyramid SPA & MK Cell License Update
March 25, 2026
Schedule One - Roquefort Therapeutics PLC
March 2, 2026
Transaction Update & Notice of Intention to Delist
February 25, 2026
Research Note Published
January 15, 2026
Clinical Trial & License Agreement Update
December 12, 2025
Conversion of CLNs
December 9, 2025
Ex-Entitlement Date - Unlisted RNV Shares
December 1, 2025
Holding(s) in Company
November 25, 2025
Director/PDMR Shareholding
November 24, 2025
Executed License Agreement & Transaction Update
November 18, 2025
MK Cell Out-License & Lyramid SPA Update
November 3, 2025
Fundraise & Transaction Update
October 16, 2025
Interim Results to 30 June 2025
September 30, 2025
Investor Presentation via Engage Investor
September 24, 2025
Proposed Acquisition of Clinical Stage Company
September 8, 2025
Lyramid SPA 2nd Extension & Carve Out
August 28, 2025
Lyramid SPA Extension
June 27, 2025
Results of AGM
June 26, 2025
Issue of Equity
June 13, 2025
Notice of Annual General Meeting
June 2, 2025
Extension of Convertible Loan Notes
May 23, 2025
Corporate Update
May 13, 2025
Annual Report & Financial Statements - 31 Dec 2024
April 30, 2025
Private Placing and Conversion of CLNs
March 14, 2025
Board Changes
March 10, 2025
Update on Sale of Lyramid
March 4, 2025
Share Purchase Agreement Signed - Sale of Lyramid
February 3, 2025
Proposed Sale of Midkine Portfolio
January 2, 2025
Director Share Distribution
December 4, 2024
Conversion of Convertible Loan Notes
November 7, 2024
STAT-6 siRNA Presentation
November 6, 2024